RxDoctor Payments Data

Christopher Bianco

Advanced Heart Failure and Transplant Cardiology · Morgantown, WVNPI 1285877688

Payments from drug & device makers

$268,641in general payments, 2019–2025

Across 156 payments — averaging $1722.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$145K
  • AstraZeneca$76K
  • Pfizer$40K
  • Alnylam Pharmaceuticals Inc.$6K
  • Bristol Myers Squibb$494
  • Abbott$457
  • plus $947 from 9 others

What the payments were for

  • Consulting fees$5,1354%
  • Speaking & faculty fees$99,49985%
  • Travel & lodging$8,9918%
  • Food & beverage$3,7703%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in West Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$61,145
Medicare patients
913
Services billed
1,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis144$3,111,912
VyndaqelTafamidis Meglumine47$1,054,339
CamzyosMavacamten45$368,243
EntrestoSacubitril/Valsartan142$156,955
EliquisApixaban110$95,549
JardianceEmpagliflozin68$82,431
FarxigaDapagliflozin Propanediol62$46,835
XareltoRivaroxaban26$30,782
CorlanorIvabradine Hcl15$13,741
Eplerenone54$2,585
Metoprolol Succinate213$2,311
Spironolactone261$2,101
Atorvastatin Calcium125$1,473
Amiodarone Hcl37$1,150
Torsemide44$1,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$39,899$4,261,801301 claims
E.r. Squibb & Sons, L.L.C.Camzyos$144,840$368,24345 claims
NovartisEntresto$17$156,955142 claims
Boehringer IngelheimJardiance$34$82,43168 claims
AstraZenecaFarxiga$75,855$46,83562 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in West Virginiaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Morgantown

Where these figures come from

Is this you, or does something look wrong? →